Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ROBERT TEMPLE: an eye for data. Interview.

Robert Temple

    Molecular Interventions
    |December 24, 2004
    PubMed
    Summary
    This summary is machine-generated.

    Robert Temple, a long-time Food and Drug Administration (FDA) leader, champions science-driven consumer advocacy. His career focuses on improving drug development, patient safety, and regulatory policy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Closing the gap: A United States perspective on enhancing drug evaluation in older adults.

    Journal of the American Geriatrics Society·2024
    Same author

    Participation of Older Adults in Clinical Trials for New Drug Applications and Biologics License Applications From 2010 Through 2019.

    JAMA network open·2022
    Same author

    Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants: A Randomized Clinical Trial.

    JAMA network open·2022
    Same author

    Roadmap to 2030 for Drug Evaluation in Older Adults.

    Clinical pharmacology and therapeutics·2021
    Same author

    U.S. racial and ethnic participation in global clinical trials by therapeutic areas.

    Journal of clinical pharmacy and therapeutics·2021
    Same author

    Encouragement of subgroup assessment by the FDA.

    Pharmaceutical statistics·2021
    Same journal

    Spindle poisons and cell fate: a tale of two pathways.

    Molecular interventions·2011
    Same journal

    CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle.

    Molecular interventions·2011
    Same journal

    Finding homes for orphan cytochrome P450s: CYP4V2 and CYP4F22 in disease states.

    Molecular interventions·2011
    Same journal

    New therapeutic approaches to combat arterial thrombosis: better drugs for old targets, novel targets, and future prospects.

    Molecular interventions·2011
    Same journal

    The secrets of a successful clinical trial: compliance, compliance, and compliance.

    Molecular interventions·2011
    Same journal

    Asthma therapeutics: recent strides, new hurdles.

    Molecular interventions·2011
    See all related articles

    Area of Science:

    • Medical Science
    • Regulatory Affairs
    • Public Health Policy

    Background:

    • Dr. Robert Temple has dedicated over 30 years to the Food and Drug Administration (FDA).
    • His career trajectory includes endocrinology research at the National Institutes of Health (NIH) before transitioning to consumer advocacy at the FDA in the 1970s.
    • Temple's tenure at the FDA coincided with significant transformations in drug regulation and patient safety initiatives.

    Discussion:

    • Temple emphasizes a critical evaluation of scientific data for informed decision-making.
    • He possesses expertise in drug action mechanisms, experimental design, and regulatory policy development.
    • Discussion extends to the societal impact of direct-to-consumer drug advertising.

    Key Insights:

    • A sustained commitment to scientific principles is crucial for effective regulatory oversight.

    Related Experiment Videos

  • Balancing innovation in drug development with stringent patient safety standards is paramount.
  • Understanding the social implications of pharmaceutical marketing is vital for public health.

    • Outlook:

    • Continued focus on rigorous data evaluation to guide regulatory decisions.
    • Adapting to evolving challenges in drug development and patient safety.
    • Addressing the complex interplay between pharmaceutical promotion and consumer health outcomes.